Kailera shares sit near April IPO price as key obesity drug data stay years away

Kailera Therapeutics (NASDAQ: KLRA) is trading close to where public investors first bought in, and the most important results for its obesity drugs are still years away. Shares closed at $16.21 on August 28, 2026, down 12.5% for the day and just 1.3% above the $16 price set in its April initial public offering ^[2]. The stock had opened at $26 on its first day of trading ^[2]. Ten days earlier, it closed at $18.51, down about 28.8% since trading began in April, with a market value of $2.40 billion ^[1].

Kailera has no approved product and no revenue ^[1]. As of June 30, 2026, it held $1.172 billion in cash and marketable securities — roughly $9.04 a share and about 56% of its market value at the August 28 close ^[2]. Management has said that money funds operations into mid-2028 ^[2]. Second-quarter research and development spending was $101.1 million, and the net loss was $111.3 million, compared with $28.9 million a year earlier ^[2]. An earlier report put the quarterly net loss at $111.31 million ^[1].

Ribupatide injection (KAI-9531) is an investigational GLP-1/GIP dual agonist — the same receptor class as tirzepatide (Mounjaro and Zepbound). It anchors a global Phase 3 program called KaiNETIC that spans three trials and more than 4,700 participants and tests weekly doses up to 10 milligrams over 76 weeks, with data expected in 2028 ^[1][2]. A 264-person U.S. Phase 2b study of a higher dose is fully enrolled, with data expected in mid-2027 ^[1][2]. An oral form of ribupatide is set to begin global Phase 3 trials in the first half of 2027 ^[2].

Three more programs sit behind it. KAI-7535 is in global Phase 2 with about 320 participants planned and data due in 2027, and the tri-agonist KAI-4729 is expected to start Phase 1 by the end of 2026 with data in 2027 ^[1][2]. In July 2026, a China Phase 3 obesity study of KAI-7535 reported up to 11.1% mean weight loss, with nausea in about 70% of treated patients and vomiting in more than 65% ^[2]. Kailera is testing lower starting doses and slower dose increases in the global Phase 2 trial, aiming to balance weight loss against tolerability; those results have not been reported yet ^[2].

The company licenses its obesity drugs from Jiangsu Hengrui Pharmaceuticals, which held 19.9% of shares at issuance, and its rights exclude China, Hong Kong, Macau and Taiwan ^[1]. Kailera has paid $100 million upfront, issued preferred shares valued at about $96.4 million at issuance, and made a $10.0 million technology transfer payment. Up to $200 million in clinical and regulatory milestones and up to $5.725 billion in commercial milestones remain, plus tiered royalties from low-single-digit to low-tens percentages of net sales ^[1]. Analyst tallies differ: seven analysts rate the shares Buy or Strong Buy with a mean target of $42.40 in one count ^[1], while another count of five analysts shows an average target of $42.75 ^[2].

Why it matters for patients

Ribupatide and the other Kailera compounds are investigational. None is approved by the FDA, and none can be prescribed. Kailera says its cash lasts into mid-2028, which matches the expected timing of the Phase 3 ribupatide readout — leaving little room for a major delay without new money, a partner or a buyer ^[2].

Gastrointestinal side effects are the most visible open question. The China KAI-7535 data showed nausea in about 70% of treated patients and vomiting in more than 65% ^[2]. Whether slower dose increases lower those rates in the global trials has not been reported.

How many obesity treatment options reach the U.S. market depends partly on whether investors keep funding companies through multi-year gaps between data readouts. Kailera is pre-commercial, unprofitable, and its lead data are not due until 2028 ^[1][2]. The August 28 decline came with no new company release or SEC filing, and the broader biotech sector also fell — the SPDR S&P Biotech ETF lost 3.46% that day, while Eli Lilly fell 0.18% and Novo Nordisk 1.42% ^[2].

What happens next

• September 23–24, 2026: Bernstein Healthcare Forum, where Kailera may give trial-enrollment and capital-allocation detail ^[2].
• September 28–October 2, 2026: EASD meeting, with ribupatide injection-site data and Hengrui metabolic data expected ^[2].
• 2027: Phase 2b high-dose ribupatide data, KAI-7535 Phase 2 data, KAI-4729 Phase 1 data, and the start of oral ribupatide Phase 3 trials ^[1][2].
• 2028: Global KaiNETIC Phase 3 ribupatide injection data ^[1][2].